Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?
- 648 Downloads
Most breast cancer (BC) tumors are early stage and hormone receptor positive, where treatment generally includes adjuvant endocrine treatment (ET). Oncology providers and women about to start ET want to know about side effects, including potential weight gain. The aim of this study was a literature review to identify the independent effect of ET on post-diagnosis weight gain. Weight gain is of concern with regard to potential associations with BC recurrence, mortality, and quality of life in survivorship. We conducted a targeted review of the literature. Thirty-eight studies met our inclusion criteria. Patient-reported weight gain ranged widely from 18 to 52 % of patients in Year 1 and from 7 to 55 % in Year 5. Some studies reported categories of weight change: lost weight (9–17 %), stable weight (47–64 %), and gained weight (27–36 %). Most studies comparing ET with placebo or tamoxifen with AI reported no significant difference between the two groups. Wide-ranging and inconsistent results point to the need for further research to clarify annual weight change (loss, gain, stability) from BC diagnosis through 5 years of ET and beyond. There is also a need to explore weight change by type of ET and to explore risk factors for weight gain in women on ET, including tumor type, sociodemographic characteristics, and health behaviors. More specific information is needed to identify high-risk BC patients who could be targeted for weight management interventions.
KeywordsBreast cancer Weight gain Endocrine treatment
This work was supported by funding from the University Cancer Research Fund of the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.
Compliance with ethical standards
Conflict of interest
- 22.Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 97(5):519–526, 529; quiz 527–518Google Scholar
- 23.Surveillance Epidemiology and End Results (SEER) (2016) Breast cancer: SEER fact sheets. National Cancer Institute. 2016. http://seer.cancer.gov/statfacts/html/breast/html. Accessed 02 Aug 2016
- 29.Burstein HJ, Griggs JJ, Prestrud AA, Temin S (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 6(5):243–246Google Scholar
- 39.Lorizio W, Wu AH, Beattie MS et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. 132(2):1107–1118Google Scholar
- 42.Zivian MT, Salgado B (2008) Side effects revisited: women’s experiences with aromatase inhibitors. Breast Cancer Action, San FranciscoGoogle Scholar
- 66.McGowan P, Perry M, Hewett J, Ge B, Sanfilippo K (2006) Weight gain in breast cancer patients: tamoxifen versus anastrozole. J Clin Oncol 24(18S (June 20 Suppl)):10544Google Scholar
- 70.Lim U, Wilkens LR, Albright CL, Novotny R, Le Marchand L, Kolonel LN (2013) University of Hawai’i Cancer Center Connection: bias in self-reported anthropometry in relation to adiposity and adulthood weight gain among postmenopausal Caucasian and Japanese American Women. Hawai’i J Med Public Health 72(12):445–449Google Scholar
- 72.Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD et al (2009) Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 18(5):1403–1409PubMedPubMedCentralCrossRefGoogle Scholar
- 75.Boonstra A, van Zadelhoff J, Timmer-Bonte A, Ottevanger PB, Beurskens CHG, van Laarhoven HWM (2013) Arthralgia during aromatase inhibitor treatment in early breast cancer. Cancer Nurs 1–8Google Scholar
- 83.Ganz PA, Cecchini RS, Julian TB et al (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10027):857–865PubMedCrossRefGoogle Scholar